RxDoctor Payments Data

Carl Russell, MD

Family Medicine · Pell City, ALNPI 1427317494

Payments from drug & device makers

$9,610in general payments, 2019–2025

Across 691 payments — averaging $13.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$848
  • Amgen$702
  • GSK$560
  • Johnson & Johnson$554
  • Bayer$497
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,610 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$159,684
Medicare patients
296
Services billed
7,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide339$377,403
EliquisApixaban745$265,458
JardianceEmpagliflozin243$207,224
MounjaroTirzepatide174$202,797
TrulicityDulaglutide80$102,642
Trelegy ElliptaFluticasone/Umeclidin/Vilanter115$83,464
XareltoRivaroxaban223$55,194
VraylarCariprazine Hcl38$52,721
Repatha SureclickEvolocumab70$47,758
FarxigaDapagliflozin Propanediol116$47,229
LinzessLinaclotide62$46,998
RybelsusSemaglutide29$45,063
BelsomraSuvorexant66$34,203
MyrbetriqMirabegron124$25,935
Soliqua 100-33Insulin Glargine/Lixisenatide26$24,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,029$422,466368 claims
Lilly USA, LLCMounjaro, Trulicity$300$305,439254 claims
PfizerEliquis, Abrysvo$461$274,915775 claims
Boehringer IngelheimJardiance$194$207,224243 claims
GSKTrelegy Ellipta, Anoro Ellipta$560$105,886158 claims
AbbVieVraylar, Linzess$848$99,720100 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$396$72,096158 claims
Johnson & JohnsonXarelto$554$55,194223 claims
MerckBelsomra, Januvia$223$50,219107 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$392$24,76726 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$195$6,76813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Pell City

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →